McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
Division of Abdominal Transplantation, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
Pediatr Transplant. 2021 May;25(3):e13868. doi: 10.1111/petr.13868. Epub 2020 Nov 9.
The clinical course of COVID-19 in pediatric solid organ transplant recipients remains ambiguous. Though preliminary experiences with adult transplant recipients have been published, literature centered on the pediatric population is limited. We herein report a multi-center, multi-organ cohort analysis of COVID-19-positive transplant recipients ≤ 18 years at time of transplant. Data were collected via institutions' respective electronic medical record systems. Local review boards approved this cross-institutional study. Among 5 transplant centers, 26 patients (62% male) were reviewed with a median age of 8 years. Six were heart recipients, 8 kidney, 10 liver, and 2 lung. Presenting symptoms included cough (n = 12 (46%)), fever (n = 9 (35%)), dry/sore throat (n = 3 (12%)), rhinorrhea (n = 3 (12%)), anosmia (n = 2 (8%)), chest pain (n = 2 (8%)), diarrhea (n = 2 (8%)), dyspnea (n = 1 (4%)), and headache (n = 1 (4%)). Six patients (23%) were asymptomatic. No patient required supplemental oxygen, intubation, or ECMO. Eight patients (31%) were hospitalized at time of diagnosis, 3 of whom were already admitted for unrelated problems. Post-transplant immunosuppression was reduced for only 2 patients (8%). All symptomatic patients recovered within 7 days. Our multi-institutional experience suggests the prognoses of pediatric transplant recipients infected with COVID-19 may mirror those of immunocompetent children, with infrequent hospitalization and minimal treatment, if any, required.
COVID-19 在儿科实体器官移植受者中的临床病程仍不明确。虽然已经发表了一些关于成人移植受者的初步经验,但以儿科人群为中心的文献有限。在此,我们报告了一项多中心、多器官队列分析,纳入了移植时年龄≤18 岁的 COVID-19 阳性移植受者。数据通过各机构的电子病历系统收集。各机构的审查委员会批准了这项跨机构研究。在 5 个移植中心中,共回顾了 26 例(62%为男性)患者,中位年龄为 8 岁。6 例为心脏移植受者,8 例为肾脏移植受者,10 例为肝脏移植受者,2 例为肺移植受者。首发症状包括咳嗽(n=12(46%))、发热(n=9(35%))、咽干/咽痛(n=3(12%))、流涕(n=3(12%))、嗅觉丧失(n=2(8%))、胸痛(n=2(8%))、腹泻(n=2(8%))、呼吸困难(n=1(4%))和头痛(n=1(4%))。6 例(23%)患者无症状。无患者需要补充氧气、插管或 ECMO。8 例(31%)患者在诊断时住院,其中 3 例因其他无关问题已住院。仅 2 例(8%)患者减少了移植后免疫抑制治疗。所有有症状的患者在 7 天内康复。我们的多机构经验表明,感染 COVID-19 的儿科移植受者的预后可能与免疫功能正常的儿童相似,住院频率较低,如果需要治疗,也很少。